FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema
Written by
American Journal Managed Care
Published
0
comments
0
min
The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.